Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie M Vose

Showing results (191-200 of 299) with videos related to

Pageof 30
Sort By:
The Lancet. Haematology|February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trialLoretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
Blood|April 7, 2021
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study resultsRanjana H Advani, Alison J Moskowitz, Nancy L Bartlett, et al.
Haematologica|April 21, 2019
ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patientsDavid Sibon, Dinh-Phong Nguyen, Norbert Schmitz, et al.
Blood|December 8, 2009
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphomaJaveed Iqbal, Dennis D Weisenburger, Timothy C Greiner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2009
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphomaMarcel P Devetten, Parameswaran N Hari, Jeanette Carreras, et al.
Leukemia & Lymphoma|April 2, 2015
Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcomeGabriel C Caponetti, Bhavana J Dave, Anamarija M Perry, et al.
Blood|July 22, 2021
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell ProjectRanjana H Advani, Tetiana Skrypets, Monica Civallero, et al.
Cancer Research Communications|April 30, 2024
Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical EffectsAlexandria P Eiken, Audrey L Smith, Sydney A Skupa, et al.
British Journal of Haematology|February 11, 2014
MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximabAnamarija M Perry, Yuridia Alvarado-Bernal, Javier A Laurini, et al.
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
Pageof 30

Showing results (191-200 of 299) with videos related to

Sort By:
Pageof 30
The Lancet. Haematology|February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trialLoretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
Blood|April 7, 2021
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study resultsRanjana H Advani, Alison J Moskowitz, Nancy L Bartlett, et al.
Haematologica|April 21, 2019
ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patientsDavid Sibon, Dinh-Phong Nguyen, Norbert Schmitz, et al.
Blood|December 8, 2009
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphomaJaveed Iqbal, Dennis D Weisenburger, Timothy C Greiner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2009
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphomaMarcel P Devetten, Parameswaran N Hari, Jeanette Carreras, et al.
Leukemia & Lymphoma|April 2, 2015
Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcomeGabriel C Caponetti, Bhavana J Dave, Anamarija M Perry, et al.
Blood|July 22, 2021
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell ProjectRanjana H Advani, Tetiana Skrypets, Monica Civallero, et al.
Cancer Research Communications|April 30, 2024
Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical EffectsAlexandria P Eiken, Audrey L Smith, Sydney A Skupa, et al.
British Journal of Haematology|February 11, 2014
MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximabAnamarija M Perry, Yuridia Alvarado-Bernal, Javier A Laurini, et al.
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
Pageof 30